Drug interactions with grapefruit juice

British Journal of Medical Practitioners

Volumn 5, Issue 4, 2013, Pages

  Mazi Kotwal, Nadeem ^a   Seshadri, Madhavan ^a  

^a South Essex Partnership University NHS Foundation Trust ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; AMIODARONE; BUSPIRONE; CARBAMAZEPINE; CLOMIPRAMINE; CLOPIDOGREL; CYTOCHROME P450 3A4; DASATINIB; DIAZEPAM; DOMPERIDONE; DRONEDARONE; ERYTHROMYCIN; EVEROLIMUS; FELODIPINE; FENTANYL; KETAMINE; MARAVIROC; MIDAZOLAM; NILOTINIB; PAZOPANIB; PIMOZIDE; PRIMAQUINE; QUETIAPINE; QUINIDINE; QUININE; SERTRALINE; SUNITINIB; UNINDEXED DRUG; VANDETANIB; ZIPRASIDONE;

ARTICLE; DRUG BIOAVAILABILITY; DRUG RESEARCH; ENZYME INHIBITION; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; INTESTINE MUCOSA; MEAL; UNITED KINGDOM; UNITED STATES; WESTERN EUROPE;

EID: 84873287095     PISSN: 17578515     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Lee HS. Objective measurement of red grapefruit juice color. J Agric Food Chem. 2000 May;48(5):1507-11.
2. Baekey PA, Cerda JJ, Burgin CW, Robbins FL, Rice RW, Baumgartner TG. Grapefruit pectin inhibits hypercholesterolemia and atherosclerosis in miniature swine. Clin Cardiol. 1988 Sep;11(9):597-600.
3. Cerda JJ, Normann SJ, Sullivan MP, et al.: Inhibition of atherosclerosis by dietary pectin in microswine with sustained hypercholesterolemia. Circulation 1994, 89:1247-1253
4. Office for National Statistics, United Kingdom. http://www.statistics.gov.uk
5. Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-269.
6. Bailey DG, Dresser G, Arnold JMO. Grapefruit-medication interactions: Forbidden fruit or avoidable consequences? CMAJ 2012. DOI:10.1503 /cmaj.120951
7. Bailey DG, Malcolm J, Arnold O, Spence D. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46: 101-110
8. Lundahl J, Regardh CG, Edgar B, Johnsson G: Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felopdipine in healthy subjects. Eur J Clin Pharmacol 1995, 49:61-67
9. Takanaga H, Ohnishi A, Murakami H, et al. Relationship between time after intake of grapefruit juice and the effect on the pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther 2000;67:201-14.
10. Edgar B, Bailey D, Bergstrand R, et al. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine and its potential clinical relevance. Eur J Clin Pharmacol 1992; 42: 313-7.
11. Lundahl J, Regardh CG, Edgar B, Johnsson G: Effects of grapefruit juice ingestion-pharmacokinetics and hemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997, 25:139-145.
12. Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ, LeDuc BW, Zinny MA: Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 2003, 74:121-9.
13. Jawad Kiani, Sardar Z Imam. Medicinal importance of grapefruit juice and its interaction with various drugs. Nutrition Journal 2007, 6:33 doi:10.1186/1475-2891-6-33
14. Bailey DG, Arnold JM, Bend JR, Tran LT, Spence JD. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. British Journal of Clinical Pharmacology 1995, 40(2):135-140
15. Honda Y, Ushigome F, Koyabu N, Morimoto N, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 2004, 143:856-864.
16. Romiti N, Tramonti G, Donati A, Chieli E: Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2. Life Sci 2004, 76:293-302.
17. Ross SA, Ziska DS, Zhao K, ElSohly MA: Variance of common flavonoids by brand of grapefruit juice. Fitoterapia 2000, 71:154-61.
18. Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD: Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol ther 1993, 54:589-594.
19. Bailey DG, Arnold JM, Munoz C, Spence JD: Grapefruit juicefelodipine interaction: mechanism, predictability and effect of naringin. Clin Pharmacol Ther 1993, 53:637-642.
20. Edwards DJ, Bernier SM: Naringin and naringenin are not primary CYP 3A inhibitors in grapefruit juice. Life Sci 1996, 59:1025-1030.
21. Kakar SM, Paine MF, Stewart PW, Watkins PB: 6'7'- Dihydroxybergamottin contributes to the grapefruit juice effect. Clin Pharmacol Ther 2004, 75:569-79.
22. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y:Specific CYP 3 A4 inhibitors in grapefruit juice: furocoumarin dimmers as components of drug interaction. Pharmacogenetics 1997, 7:391-396.
23. Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR: Grapefruit Juice-felodipine interaction: effect of naringin and 6, 7- dihydroxybergamottin in humans. Clin Pharmacol Ther 1998,64:248-256.
24. Guo LQ, Fukuda K, Ohta T, Yamazoe Y: Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 2000, 28:766-71.
25. James Maskalyk. Grapefruit juice: potential drug interactions. 2002; Canadian Medical Association Journal, 167 (3) 279-280.
26. Kane G, Lipsky J. Drug-grapefruit juice interactions. Mayo Clin Proc2000;75:933-42
27. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokin 1994; 26: 91-98